| 3.34 0.015 (0.45%) | 03-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.2 | 1-year : | 6.14 |
| Resists | First : | 4.45 | Second : | 5.26 |
| Pivot price | 4.12  |
|||
| Supports | First : | 3.15 | Second : | 2.62 |
| MAs | MA(5) : | 3.5 |
MA(20) : | 4.34 |
| MA(100) : | 3.46  |
MA(250) : | 2.64 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.9 |
D(3) : | 7.5 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 9.07 | Low : | 0.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CNTN ] has closed above bottom band by 10.7%. Bollinger Bands are 42.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.45 - 3.48 | 3.48 - 3.5 |
| Low: | 3.24 - 3.27 | 3.27 - 3.3 |
| Close: | 3.3 - 3.34 | 3.34 - 3.38 |
Canton Strategic Holdings, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. The company also involved in research and development of GV104, a buccal film technology, which has completed Phase 1 trial for respiratory and/or nervous system depression in military personnel and chemical incident responders; and GV023, an oral formulation of infliximab, addresses a critical limitation of the IV gold standard by eliminating the treatment burden of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was founded in 2017 and is based in Red Bank, New Jersey.
Fri, 20 Mar 2026
CNTN Income Statement | CANTON STRATEGIC HOLDINGS IN (NASDAQ:CNTN) - ChartMill
Fri, 20 Mar 2026
CNTN News | CANTON STRATEGIC HOLDINGS IN (NASDAQ:CNTN) - ChartMill
Thu, 19 Mar 2026
CNTN Financials: Income Statement, Balance Sheet & Cash Flow | Canton Strategic Holdings - Stock Titan
Thu, 19 Mar 2026
What is the current Price Target and Forecast for Canton Strategic Holdings, Inc. (CNTN) - Zacks Investment Research
Thu, 12 Mar 2026
BitGo to Securely Store Digital Asset Treasury Holdings for Canton Strategic Holdings, Inc. - The Chronicle-Journal
Tue, 03 Mar 2026
Canton Strategic Holdings CEO joins Canton Foundation board - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 16.5 (%) |
| Held by Institutions | 16.2 (%) |
| Shares Short | 2,580 (K) |
| Shares Short P.Month | 1,420 (K) |
| EPS | -3.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -99.8 % |
| Return on Equity (ttm) | -225.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.91 |
| PEG Ratio | 0 |
| Price to Book value | 3.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|